Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0CSH8)

• Drug Name: 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole Drug Info
• Synonyms: 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE; CHEMBL383990; 3-(1H-1,3-benzodiazol-2-yl)-2H-indazole; 2-(2H-indazol-3-yl)-1H-1,3-benzodiazole; IDZ; 1097816-83-5; Indazole Compound 2; 2c3l; AC1Q4XAS; AC1NS1P1; SCHEMBL311148; BDBM16590; 3-benzimidazol-2-yl-1h-indazole; JTKFRFMSUBOCIQ-UHFFFAOYSA-N; MolPort-016-542-829; ZINC14961821; AKOS009356321; NE25942; MCULE-6782886882; DB07959; 2-(1H-indazol-3-yl)-1H-benzimidazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-Indazole-3-yl)-1H-benzoimidazole; EN300-70692

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 135464491
  TTD Drug ID: DM0CSH8

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[3]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[4]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[5]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[6]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[7]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[8]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[9]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[10]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[12]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[13]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[14]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[15]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[7]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[16]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[17]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[18]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[19]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[21]

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[22]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[23]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[11]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[25]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[26]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[27]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[28]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[29]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[30]

Drug(s) Targeting VEGFR1 messenger RNA (VEGFR1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[31]
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[32]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[18]
Sirna-027	DMZTQD8	Exudative age-related macular degeneration	9B78.3Z	Phase 1/2	[33]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[34]
AAL-993	DM35RFH	Discovery agent	N.A.	Investigative	[32]
PMID17935989C25	DML8ZBR	Discovery agent	N.A.	Investigative	[35]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	DMX6QMT	Discovery agent	N.A.	Investigative	[36]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	DMI3OR9	Discovery agent	N.A.	Investigative	[37]
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	DMQWD75	Discovery agent	N.A.	Investigative	[36]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[13]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[3]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[38]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[39]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[40]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[41]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[42]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[43]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[44]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[45]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[1]
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Inhibitor	[2]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[2]
VEGFR1 messenger RNA (VEGFR1 mRNA)	TT1VAUK	VGFR1_HUMAN	Inhibitor	[2]

References

• [1] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [2] Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
• [3] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [6] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [7] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [8] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [10] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [13] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [14] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [17] National Cancer Institute Drug Dictionary (drug id 452042).
• [18] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [19] Company report (Neuronova)
• [20] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [21] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [22] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
• [23] Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
• [24] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [25] A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
• [26] National Cancer Institute Drug Dictionary (drug id 730054).
• [27] Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
• [28] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [29] Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
• [30] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [31] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [32] Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
• [33] 2011 Pipeline of Sirna Therapeutics.
• [34] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [35] Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
• [36] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
• [37] Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
• [38] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [39] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [40] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [41] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [42] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [43] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [44] Clinical pipeline report, company report or official report of Exelixis (2011).
• [45] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services